Companies · Pharmaceuticals

GRAM Acquisition, LLC

GRAND RAPIDS · Pharmaceuticals

Diligence memoA one-page analyst read on GRAM Acquisition, LLC — recommendation, valuation, rhythm, risks.
$3.3M
Total raised · real
2
Rounds
0.3×
Latest step-up
Top 66%
Sector rank · raised
Seed
Latest stage · inferred · Mon Jan 21 2013 00:00:00 GMT+0000 (Coordinated Universal Time)

GRAM Acquisition, LLC looks under-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.47× the median modeled value of Seed Pharmaceuticals companies in 2013–2015 (51 peers) — value vs value, same stage and era.
Dormant
  • Last raise 13.4 yr ago; this sector typically re-raises about every 13 months.
  • Silent for over 3× the sector's normal cadence.

Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.

Issuer-vehicle patternmedium confidence

GRAM Acquisition, LLC behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.

Issuer structure
Company-like
No recurring-offering pattern strong enough to override normal financing interpretation.
Lifecycle
15.6 yr record
Peak capital year was 2010 with $2.4M across 1 filings.
Market position
ahead of 35% of Pharmaceuticals peers
Capital scale is ahead of 35% of Pharmaceuticals peers; modeled value is above 34% of peers by modeled value. Large capital with mid-pack modeled value can signal an issuer/program profile rather than operating-company growth.
Valuation reliability
Normal applicability
Stage/dilution valuation models are weakest when the issuer is broad-sector, recurring, or vehicle-like.
Operating evidence
Sparse
No clear CEO/founder/principal role is surfaced, so operating-company confidence is lower.
Data quality
Consistent
Canonical totals and visible filing detail are broadly aligned.
What triggered this
  • Legal name looks like an issuer vehicle rather than a product company.
  • No clearly named CEO/founder/principal role in the public records surfaced here.
  • No verified homepage on the profile yet.
  • Capital program peaked in 2010: $2.4M across 1 filings.
  • Largest single filing was $2.4M on 2010-12-08.
How to read the page
  • Read this less like a startup funding journey and more like a capital-raising program.
  • Stage-based valuation and peer labels have lower applicability for this pattern.
  • The more important signal is lifecycle: repeated filings ended years ago, so current activity needs outside confirmation.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Pharmaceuticals

GRAM Acquisition, LLC is one of 1610 Pharmaceuticals companies tracked from GRAND RAPIDS. By capital raised it ranks in the long tail (ahead of 35% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$25M$50M$75M$100MSeed · 2010-12-08 Raised $2.4M (real) Modeled valuation $93M (est)$2.4M$93MSeed2010Seed · 2013-01-21 Raised $818K (real) Modeled valuation $31M (est)$818K$31MSeed2013+$818KCumulative $3.3M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Seed$2.4M · 2010
Seed extension$818K · 2013

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 50%.

Modeled valuation trajectory
$31.1M
Base estimate est.
$619K
Conservative case
$244.3M
Upside case
$4.1M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Seeda $1.0M–$4.0M round). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.

Seed · modeled $92.7M · 2010-12-082010Seed · modeled $31.1M · 2013-01-212013
Model inputs · modeled:benchmark-stage-stepup-v1
20%
Dilution assumption
Implied ownership sold in the financing.
34%
Survival probability
15% low · 52% high
1.68×/yr
Annual markup
2.20×/yr upside case
6.0 yr
Elapsed time used
13.4 yr actual, capped for stale marks
pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
25 mo
Avg between rounds
$1.5M/yr
Capital velocity
15.6 yr
On record since
2010
First round
2
Rounds on file
How it compares to the market

Benchmarked against 1610 companies in Pharmaceuticals. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.4× of median
This company$3.3M
Sector median$8.1M
Latest round — vs other Seed rounds in sector (real $, this stage) 0.5× of median
This company$818K
Sector median$1.7M
Modeled value — vs sector median (estimate, all stages) 0.4× of median
This company$31.1M
Sector median$76.1M

Raised more than 35% of sector peers (real $). Modeled value above 34% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #43 of 51.

This companyCohort peer
$10.0M$100.0M$1.0B$1.0M$10.0M$100.0MCapital raised (log)Assured Pharma, Inc. · Seed Raised $3.9M · modeled $147.4M (est)Wellesley Pharmaceuticals Llc · Seed Raised $4.7M · modeled $143.7M (est)Generico, Llc · Seed Raised $4.2M · modeled $143.0M (est)Aggamin Pharmaceuticals, LLC · Seed Raised $3.7M · modeled $141.6M (est)Abeona Therapeutics LLC · Seed Raised $3.6M · modeled $137.4M (est)Arvinas, Inc. · Seed Raised $3.5M · modeled $133.6M (est)Dignify Therapeutics, LLC · Seed Raised $3.4M · modeled $131.1M (est)Smsa Crane Acquisition Corp. · Seed Raised $3.4M · modeled $128.3M (est)Gemmus Pharma Inc. · Seed Raised $4.8M · modeled $125.5M (est)Healthcare Corp of America · Seed Raised $3.2M · modeled $121.7M (est)Wapta LLC · Seed Raised $3.0M · modeled $114.1M (est)Tesla Life Sciences, LLC · Seed Raised $11.2M · modeled $113.7M (est)GRAM Acquisition, LLC (this company) Raised $3.3M · modeled $31.1M (est)GRAM Acquisition, LLC
CompanyStageRaised · realValue · estvs peer med.
Assured Pharma, Inc.Seed$3.9M$147.4M2.22×
Wellesley Pharmaceuticals LlcSeed$4.7M$143.7M2.17×
Generico, LlcSeed$4.2M$143.0M2.16×
Aggamin Pharmaceuticals, LLCSeed$3.7M$141.6M2.14×
Abeona Therapeutics LLCSeed$3.6M$137.4M2.07×
Arvinas, Inc.Seed$3.5M$133.6M2.02×
Dignify Therapeutics, LLCSeed$3.4M$131.1M1.98×
Smsa Crane Acquisition Corp.Seed$3.4M$128.3M1.94×
Gemmus Pharma Inc.Seed$4.8M$125.5M1.89×
Healthcare Corp of AmericaSeed$3.2M$121.7M1.84×
Wapta LLCSeed$3.0M$114.1M1.72×
Tesla Life Sciences, LLCSeed$11.2M$113.7M1.72×
GRAM Acquisition, LLC this companySeed$3.3M$31.1M0.47×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Seed$2.4M2010-12-08$12.2M$92.7M90%
Seed$818K2013-01-21$4.1M$31.1M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Seed$2.4M2010-12-08
    • First recorded raise — entered as Seed.
  2. Seed$818K2013-01-21
    • Raised again after 25 mo — slower than the ~13 mo sector norm.
    • Round 3.0× smaller than the prior — bridge or down round.
Intelligence
2015 ~Q1
Modeled next raise · ~25mo cadence
$818K
Modeled next size est.range $818K$1.3M
0.3×
Last step-up
$1.5M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Dale . Grogan6 other2010-12
John Kerschen4 other2010-12
Connie Degen2 other2010-12
Jerry Arthur2 other2010-12
Doug Conner1 other2010-12
Connie Degan2013-01
Registry & provenance

GRAM Acquisition, LLC is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1507659
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
GRAM NewCo, Inc.PharmaceuticalsSeries A$5.0M$153.3Mnetwork2 shared operators · same sector
Grand River Aseptic Manufacturing, Inc.Other Health CareSeries A$11.5M$7.1Mnetwork3 shared operators
nanoRETE, Inc.BiotechnologySeed$1.2M$52.8Mnetwork2 shared operators · same stage
Euclises Pharmaceuticals, Inc.PharmaceuticalsSeed$3.2M$46.3Msame sector · same stage
Esanik Therapeutics, Inc.PharmaceuticalsSeed$3.3M$13.1Msame sector · same stage
Combinent BioMedical Systems, Inc.PharmaceuticalsSeed$3.4M$22.8Msame sector · same stage
Actinobac Biomed, Inc.PharmaceuticalsSeed$3.4M$38.0Msame sector · same stage
CorMedix Inc.PharmaceuticalsSeed$3.5M$32.3Msame sector · same stage
Frequently asked
How much funding has GRAM Acquisition, LLC raised?
GRAM Acquisition, LLC has raised approximately $3.3M in disclosed capital across 2 recorded financing rounds, aggregated from public filings.
What is GRAM Acquisition, LLC's estimated valuation?
Provath's modeled valuation for GRAM Acquisition, LLC is approximately $31.1M (modeled range $619K–$244.3M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is GRAM Acquisition, LLC at?
GRAM Acquisition, LLC's latest modeled financing stage is Seed. Its most recent recorded round closed around Mon Jan 21.
What does GRAM Acquisition, LLC do and where is it based?
GRAM Acquisition, LLC operates in the Pharmaceuticals sector, based in GRAND RAPIDS.
Explore related

See where GRAM Acquisition, LLC sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at GRAM Acquisition, LLC, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.